Eight-year-old cousins Elizabeth Conlan and Julia Tremblay are fundraising to help their friend with lymphoma, Chris, go on vacation. Chris is a student of Father John V. Doyle School, and at age 11 this is his second time going through treatment for Hodgkin’s lymphoma.
“Coventry Cares for Chris” is the slogan the young girls chose for their campaign, referring to their local town of Coventry, Rhode Island.
The girls were inspired to help out Chris because they “feel so bad that he has to go through this all over again”. Elizabeth and Julia want to give him a chance to forget about his sickness for a while and just enjoy being a kid.
Read their complete letter to the community of Coventry, Rhode Island here.
In the past week, the girls have already raised over $1000. They have inspired their community to help Chris take a nice break from his sickness during his difficult journey with lymphoma.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...